NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

Volver

Resultados 59 resultados LastUpdate Última actualización 18/02/2018 [14:18:00] pdf PDF




Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 3 nextPage   Mostrar por página


GENOTYPING AND TREATMENT OF CANCER, IN PARTICULAR CHRONIC LYMPHOCYTIC LEUKEMIA

NºPublicación: WO2018029254A1 15/02/2018

Solicitante:
MEDIZINISCHE UNIV WIEN [AT]

Resumen de: WO2018029254A1

The present invention relates to the field of genotyping and treating cancer such as leukemia and lymphoma, especially chronic lymphocytic leukemia (CLL). It is an object of the present invention to provide novel tools and methods for genotyping CLL (and other cancers), in particular for predicting disease progression and informing treatment decisions or for targeted treatment of CLL (and other cancers) based on cancer genotype. Surprisingly, in the course of the present invention, deletions in the N0TCH2 gene were found in cells obtained from blood samples of CLL patients. These deletions lead to the expression of N-terminally truncated, constitutively active N0TCH2 variants. The present invention provides a polynucleotide probe for detecting a region of the human N0TCH2 gene in a cell, the sequence of the region being at least 10 consecutive nucleotides selected from the sequence according to SEQ ID NO: 1, wherein the probe is specific for the region or for its reverse complement, and wherein the probe is bound to a molecular tag. The polynucleotide probe is preferentially used in fluorescence in-situ hybridization (FISH). Moreover, the present invention provides an antibody specific for an N-terminally truncated human Notch2 protein starting with the sequence MVYP or the sequence MAKR.



traducir


 

NOVEL ANTIBODIES AND USES THEREOF

NºPublicación: US2018044425A1 15/02/2018

Solicitante:
CANTARGIA AB [SE]

Resumen de: US2018044425A1

The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting to domain 3 of human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of cancers, such as leukemias and melanoma.



traducir


 

TREATMENT OF RELAPSED AND/OR REFRACTORY SOLID TUMORS AND NON-HODGKIN'S LYMPHOMAS

NºPublicación: WO2018031658A1 15/02/2018

Solicitante:
CELGENE CORP [US]

Resumen de: WO2018031658A1

Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).



traducir


 

Use of ureidomustine (BO-1055) in cancer treatment

NºPublicación: AU2016308116A1 15/02/2018

Solicitante:
ACAD SINICA
MEMORIAL SLOAN KETTERING CANCER CENTER

Resumen de: AU2016308116A1

Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymphoblastic leukemia (B-ALL)], lymphomas, small lung cell carcinoma (SCLC), sarcomas, and others.



traducir


 

EFFICACY OF ANTI-HLA-DR ANTIBODY DRUG CONJUGATE IMMU-140 (hL243-CL2A-SN-38) IN HLA-DR POSITIVE CANCERS

NºPublicación: WO2018031408A1 15/02/2018

Solicitante:
IMMUNOMEDICS INC [US]

Resumen de: WO2018031408A1

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-HLA-DR antibody or antigen-binding antibody fragment. The immunoconjugate may be administered at a dosage of between 3 mg/kg and 18 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg, more preferably 8, 10 or 12 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. The methods and compositions are particularly useful for treating AML, ALL or multiple myeloma.



traducir


 

COMBINATION TREATMENT PROTOCOL

NºPublicación: US2018042887A1 15/02/2018

Solicitante:
BIONOMICS LTD [AU]

Resumen de: US2018042887A1

The present disclosure provides a combination and a method for treating chronic lymphocytic leukemia (CLL).



traducir


 

THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND APPLICATIONS

NºPublicación: WO2018028721A1 15/02/2018

Solicitante:
UNIV XIAMEN [CN]

Resumen de: WO2018028721A1

The present invention relates to a thienopyrimidine compound, a preparation method therefor, a pharmaceutical composition, and applications. Specifically, the present invention relates to a compound having ALK and/or c-Met selective inhibitory activity, a preparation method for the compound, a pharmaceutical composition including the compound, a use of the compound in the preparation of a drug used for preventing or treating diseases related to anaplastic lymphoma kinase in organisms, and a use of the compound in the preparation of a drug used for preventing or treating diseases related to angiogenesis or cancer metastasis, especially a use of the compound in the preparation of a drug used for preventing or treating tumour growth and metastasis.



traducir


 

GENOTYPING AND TREATMENT OF CANCER, IN PARTICULAR CHRONIC LYMPHOCYTIC LEUKEMIA

NºPublicación: EP3282019A1 14/02/2018

Solicitante:
MEDIZINISCHE UNIVERSIT\u00C4T WIEN [AT]

Resumen de: EP3282019A1

The present invention relates to the field of genotyping and treating cancer such as leukemia and lymphoma, especially chronic lymphocytic leukemia (CLL). It is an object of the present invention to provide novel tools and methods for genotyping CLL (and other cancers), in particular for predicting disease progression and informing treatment decisions or for targeted treatment of CLL (and other cancers) based on cancer genotype. Surprisingly, in the course of the present invention, deletions in the NOTCH2 gene were found in cells obtained from blood samples of CLL patients. These deletions lead to the expression of N-terminally truncated, constitutively active NOTCH2 variants. The present invention provides a polynucleotide probe for detecting a region of the human NOTCH2 gene in a cell, the sequence of the region being at least 10 consecutive nucleotides selected from the sequence according to SEQ ID NO: 1, wherein the probe is specific for the region or for its reverse complement, and wherein the probe is bound to a molecular tag. The polynucleotide probe is preferentially used in fluorescence in-situ hybridization (FISH). Moreover, the present invention provides an antibody specific for an N-terminally truncated human Notch2 protein starting with the sequence MVYP or the sequence MAKR.



traducir


 

Y-90-LABELED ANTI-CD22 ANTIBODY (EPRATUZUMAB TETRAXETAN) IN REFRACTORY/RELAPSED ADULT CD22+ B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

NºPublicación: EP3280453A1 14/02/2018

Solicitante:
IMMUNOMEDICS INC [US]
CHU DE NANTES [FR]
INSERM - INSTITUT NATIONAL DE LA SANT\u00C9 ET DE LA RECH M\u00C9DICALE [FR]
THE UNIV OF NANTES [FR]

Resumen de: WO2016164264A1

The present invention relates to use of 90Y-conjugated anti-CD22 antibody for treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). Preferably the anti-CD22 antibody is epratuzumab tetraxetan. More preferably, the radiolabeled antibody is administered at a dosage of between 2.5 and 10.0 mCi/m2, most preferably on days 1 and 8 of the cycle. In specific embodiments, the dosage may be 2.5, 5.0, 7.5 or 10.0 mCi/m2. The radiolabeled antibody is capable of inducing a complete response in individuals with relapsed/refractory ALL.



traducir


 

CD9 AS A THERAPEUTIC TARGET FOR HEMATOLOGIC MALIGNANCIES

NºPublicación: US2018038865A1 08/02/2018

Solicitante:
THE CHINESE AND KNOWLEDGE TRANSFER SERVICES [CN]

Resumen de: US2018038865A1

The present invention provides a method for detecting and treating hematologic malignancies including leukemia such as acute lymphoblastic leukemia (ALL) in a subject and a method for determining disease prognosis among leukemia patients by detecting CD9 expression. A kit and device useful for such methods are also provided. In addition, the present invention provides a composition for treating hematologic malignancies such as leukemia by suppressing CD9 expression or activity.



traducir


 

N-(4-HYDROXY-4-METHYL-CYCLOHEXYL)-4-PHENYL-BENZENESULFONAMIDES AND N-(4- HYDROXY-4-METHYL-CYCLOHEXYL)-4-(2-PYRIDYL)BENZENESULFONAMIDES AND THEIR THERAPEUTIC USE

NºPublicación: US2018037544A1 08/02/2018

Solicitante:
PIMCO 2664 LTD [GB]

Resumen de: US2018037544A1

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as HMC compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and/or joint destruction and/or bone loss; disorders mediated by excessive and/or inappropriate and/or prolonged activation of the immune system; inflammatory and autoimmune disorders, for example, rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (COPD); asthma; atherosclerosis; inflammatory bowel disease; ankylosing spondylitis; multiple sclerosis; systemic lupus erythematosus; Sjogren's syndrome; a disorder associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or Paget's disease; cancer, such as a haematological malignancy, such as multiple myeloma, leukemia, or lymphoma, or a solid tumour cancer, such as bladder cancer, breast cancer (female and/or male), colon cancer, renal cell carcinoma, kidney cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, basal cell ameloblastoma, or melanoma; a disorder associated with fibrosis, s



traducir


 

USE OF MITOCHONDRIAL ACTIVITY INHIBITORS FOR THE TREATMENT OF POOR PROGNOSIS ACUTE MYELOID LEUKEMIA

NºPublicación: WO2018023197A1 08/02/2018

Solicitante:
UNIV MONTREAL [CA]

Resumen de: WO2018023197A1

A method for treating acute myeloid leukemia (AML), such as poor risk AML, by administering to a subject in need thereof an effective amount of a mitochondrial activity inhibitor, for example a class A electron transport chain (ETC) complex I inhibitor such as Mubritinib or a pharmaceutically acceptable salt thereof, is disclosed. The AML to be treated may be characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (NΚ), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.



traducir


 

CANCER ANTIGEN TARGETS AND USES THEREOF

NºPublicación: WO2018027197A1 08/02/2018

Solicitante:
MEMORIAL SLOAN KETTERING CANCER CENTER [US]

Resumen de: WO2018027197A1

The presently disclosed subject matter provides methods and compositions for treating myeloid disorders (e.g., acute myeloid leukemia (AML)). It relates to immunoresponsive cells bearing antigen recognizing receptors (e.g., chimeric antigen receptors (CARs)) targeting AML-specific antigens.



traducir


 

COMPOSITION TO BE USED FOR TREATING ADULT T CELL LEUKEMIA/LYMPHOMA AND METHOD FOR PRODUCING SAME

NºPublicación: WO2018025978A1 08/02/2018

Solicitante:
UNIV TOKYO [JP]

Resumen de: WO2018025978A1

[Problem] To provide a means for treating adult T cell leukemia/lymphoma. [Solution] A composition to be administered to a subject, said composition being free from valine and/or methionine.



traducir


 

TREATMENT OF LYMPHOMA USING ANTIBODY-COUPLED T CELL RECEPTOR

NºPublicación: WO2018027135A1 08/02/2018

Solicitante:
UNUM THERAPEUTICS INC [US]

Resumen de: WO2018027135A1

Disclosed herein are immune cells expressing antibody-coupled T cell receptors (ACTRs) and methods of using such in combination with anti-CD20 antibodies in treating a lymphoma.



traducir


 

COMPANION DIAGNOSTIC FOR COMBINATION LENALIDOMIDE AND ERYTHROPOIETIN TREATMENT

NºPublicación: WO2018027144A1 08/02/2018

Solicitante:
H LEE MOFFITT CANCER CENTER AND RES INSTITUTE INC [US]

Resumen de: WO2018027144A1

Disclosed herein is a companion diagnostic to predict efficacy of combination lenalidomide and erythropoietin treatment in patients with a erythropoietin (Epo)- refractory, Lower Risk (LR) Non-deletion 5q [Del(5q)] myelodysplasia syndrome (MDS). The method involves assaying erythroid precursors from a biological sample from the subject for a CD45 isoform profile, and treating the subject with a combination of lenalidomide and erythropoietin if the erythroid precursors have a predominance of large CD45RA and CD45RB isoforms compared to small CD45RO isoform.



traducir


 

Therapeutic and/or prophylactic agent for adult t cell leukemia/lymphoma

NºPublicación: AU2016299614A1 08/02/2018

Solicitante:
DAIICHI SANKYO COMPANY LIMITED
THE UNIV OF TOKYO

Resumen de: AU2016299614A1

The present invention provides a therapeutic and/or prophylactic agent for adult T cell leukemia/lymphoma comprising a compound having a specific chemical structure or a pharmaceutically acceptable salt thereof. The active ingredient of the therapeutic and/or prophylactic agent for adult T cell leukemia/lymphoma is 7-chloro-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5- carboxamide or a pharmaceutically acceptable salt thereof, or 7-bromo-2-[trans-4-(dimethylamino)cyclohexyl]-N-[(4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-2,4-dimethyl-1,3-benzodioxole-5-carboxamide or a pharmaceutically acceptable salt thereof.



traducir


 

Polycyclic amide derivatives as CDK9 inhibitors

NºPublicación: AU2016286200A1 08/02/2018

Solicitante:
ASTRAZENECA AB

Resumen de: AU2016286200A1

Provided are a series of novel pyridine or pyrimidine derivatives of Formula (I) which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative diseases such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer. A is C(R



traducir


 

ActRIIb antagonists and dosing and uses thereof

NºPublicación: AU2018200463A1 08/02/2018

Solicitante:
ACCELERON PHARMA INC

Resumen de: AU2018200463A1

In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple 5 myeloma. Methods for dosing a patient with an ActRIIb antagonist are also provided.



traducir


 

PHARMACEUTICAL COMPOSITION COMPRISING POMALIDOMIDE

NºPublicación: WO2018024646A1 08/02/2018

Solicitante:
SYNTHON BV [NL]

Resumen de: WO2018024646A1

The present invention relates to a pharmaceutical composition comprising pomalidomide, maltodextrin and a filler, wherein the weight ratio of maltodextrin to filler ranges from 1:1 to 1:2. The invention further relates to the use of said pharmaceutical composition as medicament in the treatment of multiple myeloma.



traducir


 

METHOD FOR PROGNOSING AND DIAGNOSING TUMORS

NºPublicación: WO2018024609A2 08/02/2018

Solicitante:
CBMED GMBH CENTER FOR BIOMARKER RES IN MEDICINE [AT]

Resumen de: WO2018024609A2

The present invention is in the field of tumor prognosis and relates to a method of providing a prognosis to an individual suffering from a tumor. Further, the present invention relates to a method of diagnosing a hepatocellular carcinoma (HCC) in an individual, a method of diagnosing a hepatitis C virus (HCV) infectionin an individual, a method of diagnosing a hepatitis B virus (HBV) infection in an individual, and a method of diagnosing a viral induced hepatocellular carcinoma in an individual. Furthermore, the present invention relates to a method of differentiating between at least two conditions in an individual, wherein the at least two conditions are selected from the group consisting of a hepatocellular carcinoma (HCC), hepatitis C virus (HCV) infection, hepatitis B virus (HBV) infection, and a viral induced hepatocellular carcinoma (HCC).In addition, the present invention relates to a method for diagnosing a lymphoma in an individual. More- over, the present invention relates to a kit for conducting the above mentioned methods.



traducir


 

METHODS OF TREATMENT OF MYELODYSPLASTIC SYNDROME

NºPublicación: WO2018026894A1 08/02/2018

Solicitante:
CELGENE CORP [US]

Resumen de: WO2018026894A1

Provided are methods and compositions for treating a malignancy, particularly myeloplastic syndrome in patients carrying an IDH2 mutation by administering 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin- 4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol.



traducir


 

NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS

NºPublicación: US2018037627A1 08/02/2018

Solicitante:
IMMATICS BIOTECHNOLOGIES GMBH [DE]

Resumen de: US2018037627A1

A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB



traducir


 

TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

NºPublicación: US2018037653A1 08/02/2018

Solicitante:
XENCOR INC [US]

Resumen de: US2018037653A1

The present disclosure relates to the treatment of chronic lymphocytic leukemia. Monoclonal antibody XmAb5574 is efficacious when administered to patient at certain dosage regimens.



traducir


 

OLIGONUCLEOTIDE COMPOSITIONS AND USES THEREOF

Nº publicación: US2018037890A1 08/02/2018

Solicitante:
MIRAGEN THERAPEUTICS INC [US]

Resumen de: US2018037890A1

The present invention provides oligonucleotide inhibitors of miR-155 and compositions thereof. The invention further provides methods for treating cancer such as a T cell lymphoma in a subject by administering to the subject an oligonucleotide inhibitor of miR-155. The invention also provides methods for reducing or inhibiting the proliferation of malignant T cells by administering an oligonucleotide inhibitor of miR-155.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver